What Changed in Assertio’s Fair Value Reset The latest update on Assertio Holdings centres on a very large reset in the fair ...

Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT) today announced that it has received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the ...

Assertio (ASRT) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.04 per share a year ago. These figures are ...

H.C. Wainwright analyst Raghuram Selvaraju adjusted the firm’s price target on Assertio (ASRT) to $35 from $3 and keeps a Buy rating on the shares ...

In Q1 FY2023, Assertio achieved significant progress in executing the new strategy brought on board by CEO Dan Peisert. The market expects ASRT's EPS to decline nearly 82% YoY in FY2023, but then ...

LIMA — Dr. Heather Moore, who graduated from Rhodes State College in 1990, has been elevated to serve as chair of the board of the American Society of Radiologic Technologists for the 2025-2026 term.

Assertio Holdings Inc. Annual stock financials by MarketWatch. View the latest ASRT financial statements, income statements and financial ratios.